Filtered By:
Source: American Heart Journal
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 491 results found since Jan 2013.
Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design
Publication date: Available online 7 March 2018 Source:American Heart Journal Author(s): Douglas L. Packer, Daniel B. Mark, Richard A Robb, Kristi Monahan, Tristram Bahnson, Kathleen Moretz, Jeanne Poole, Alice Mascette, Yves Rosenberg, Neal Jeffries, Hussein R. Al-Khalidi, Kerry L. Lee The Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA, NCT00911508)(1) trial is testing the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art pharmacologic therapy. This inte...
Source: American Heart Journal - March 8, 2018 Category: Cardiology Source Type: research
Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT registry®
ConclusionsIn the U.S. the majority of patients were discharged on DAPT following TAVR. Practice patterns varied significantly among hospitals. Patients discharged with DAPT had a similar adjusted risk of mortality, stroke and MI compared to antiplatelet monotherapy, though risk for bleeding was significantly higher. Future investigation is needed to define the optimal antiplatelet therapy for patients undergoing TAVR.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research
Association of Frailty and Cognitive Impairment with benefits of Oral anticoagulation in patients with atrial fibrillation
ConclusionThose with cognitive impairment or frailty in AF had higher predicted risk for stroke and higher observed mortality, yet were less likely to be treated with OAC. Despite this, the benefits of OAC were similar in patients with and without cognitive impairment or frailty.
Source: American Heart Journal - January 30, 2019 Category: Cardiology Source Type: research
Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention
Conclusion: These results suggest that radial access is not associated with an increased risk of clinically detected NCs, even during a period when there was a rapid evolution in the preferred access site for PCI in the United Kingdom. These are reassuring results, particularly for operators embarking on a change to radial access for PCI.
Source: American Heart Journal - December 26, 2012 Category: Cardiology Authors: Karim Ratib, Mamas A. Mamas, Helen C. Routledge, Peter F. Ludman, Douglas Fraser, James Nolan Tags: Transradial Angiography and Intervention Source Type: research
Temporal trends in sudden unexpected death in a general population: The Hisayama Study
Background: Studies addressing the temporal trends in the prevalence of sudden unexpected death (SUD) and its underlying causes in the general population are limited.Methods: Among a total of 1934 residents aged ≥20 years of the town of Hisayama, Japan, who died of endogenous causes of death and underwent autopsy examination (autopsy rate 78.5%) from 1962 to 2009, 204 were determined to be cases of SUD within 24 hours.Results: The trend in the age- and sex-adjusted prevalence of SUD among all autopsy subjects was stable over four 12-year periods (13.1% in 1962-1973, 13.4% in 1974-1985, 15.0% in 1986-1997, and 14.6% in 19...
Source: American Heart Journal - April 8, 2013 Category: Cardiology Authors: Masaharu Nagata, Toshiharu Ninomiya, Yasufumi Doi, Jun Hata, Fumie Ikeda, Naoko Mukai, Kazuhiko Tsuruya, Yoshinao Oda, Takanari Kitazono, Yutaka Kiyohara Tags: Acute Ischemic Heart Disease Source Type: research
Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Background: Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is not known.Design: The Cardiovascular Inflammation Reduction Trial (CIRT) (ClinicalTrials.gov NCT01594333) will randomly allocate 7,000 patients with prior myocardial infarction (MI) and either type 2 diabetes or the metabolic syndrome to low-dose methotrexate (target dose 15-20 mg/wk) or placebo over an average follow-up period of 3 to 5 years. Low-dose methotrexate is a commonly used anti-inflammatory regimen for the treatment of rheumatoid a...
Source: American Heart Journal - May 6, 2013 Category: Cardiology Authors: Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, Nina Paynter, Jean MacFadyen, Elaine Zaharris, Milan Gupta, Michael Clearfield, Peter Libby, Ahmed A.K. Hasan, Robert J. Glynn, Paul M. Ridker Tags: Trial Design Source Type: research
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
Conclusions: Comprehensive procedures were used for rigorous event reascertainment and readjudication in a previously completed open-label, global clinical trial. These procedures used in this unique situation were consistent with other common approaches in the field, were enhanced to address the FDA concerns about the original RECORD trial results, and could be considered by clinical trialists designing event readjudication protocols for drug development programs that have been completed.
Source: American Heart Journal - June 24, 2013 Category: Cardiology Authors: Renato D. Lopes, Sheila Dickerson, Gail Hafley, Shana Burns, Sandra Tourt-Uhlig, Jennifer White, L. Kristin Newby, Michel Komajda, John McMurray, Robert Bigelow, Philip D. Home, Kenneth W. Mahaffey Tags: Trial Design Source Type: research
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Conclusions: Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
Source: American Heart Journal - June 6, 2013 Category: Cardiology Authors: Kenneth W. Mahaffey, Gail Hafley, Sheila Dickerson, Shana Burns, Sandra Tourt-Uhlig, Jennifer White, L. Kristin Newby, Michel Komajda, John McMurray, Robert Bigelow, Philip D. Home, Renato D. Lopes Tags: Diabetes and Metabolism Source Type: research
Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation
Conclusions: Cardiovascular hospitalization is common in the first year after AF diagnosis. Atrial fibrillation, heart failure, myocardial infarction, and stroke/transient ischemic attack account for half of primary hospitalization diagnosis. Cardiovascular hospitalization is independently associated with mortality, irrespective of time from diagnosis to first hospitalization, and represents a critical inflection point in survival trajectory. These findings highlight the importance of CV hospitalization as a marker of disease progression and poor outcomes. Efforts to clarify the determinants of hospitalization could inform...
Source: American Heart Journal - August 12, 2013 Category: Cardiology Authors: Mintu P. Turakhia, Matthew D. Solomon, Mehul Jhaveri, Pamela Davis, Michael R. Eber, Ryan Conrad, Nicholas Summers, Darius Lakdawalla Tags: Electrophysiology Source Type: research
Response to letter by Messeri et al
We thank Dr Messeri and colleagues for their interest in our network meta-analysis on the risk of stroke in patients treated with on-pump coronary artery bypass graft (CABG), off-pump CABG, and percutaneous coronary intervention (PCI), which builds upon a prior comprehensive pairwise analysis on the same topic. The crude event rates by simple pooling of data are 148/10,957 (1.4%) for 79 studies of on-pump CABG, 72/7,119 (1.0%) for 70 studies of off-pump CABG, and 15/4,653 (0.3%) for 17 studies of PCI. From a Bayesian binomial random-effect model, the absolute risk estimate for stroke was 1.4% in patients treated with on-pu...
Source: American Heart Journal - August 19, 2013 Category: Cardiology Authors: Tullio Palmerini, Giuseppe Biondi-Zoccai, Diego Della Riva, Andrea Mariani, Gregg W. Stone Tags: Letters to the Editor Source Type: research
Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation
Conclusions: Cardiovascular hospitalization is common in the first year after AF diagnosis. Atrial fibrillation, heart failure, myocardial infarction, and stroke/transient ischemic attack account for half of primary hospitalization diagnosis. Cardiovascular hospitalization is independently associated with mortality, irrespective of time from diagnosis to first hospitalization, and represents a critical inflection point in survival trajectory. These findings highlight the importance of CV hospitalization as a marker of disease progression and poor outcomes. Efforts to clarify the determinants of hospitalization could inform...
Source: American Heart Journal - August 12, 2013 Category: Cardiology Authors: Mintu P. Turakhia, Matthew D. Solomon, Mehul Jhaveri, Pamela Davis, Michael R. Eber, Ryan Conrad, Nicholas Summers, Darius Lakdawalla Tags: Electrophysiology Source Type: research
Response to letter by Messeri et al
We thank Dr Messeri and colleagues for their interest in our network meta-analysis on the risk of stroke in patients treated with on-pump coronary artery bypass graft (CABG), off-pump CABG, and percutaneous coronary intervention (PCI), which builds upon a prior comprehensive pairwise analysis on the same topic. The crude event rates by simple pooling of data are 148/10,957 (1.4%) for 79 studies of on-pump CABG, 72/7,119 (1.0%) for 70 studies of off-pump CABG, and 15/4,653 (0.3%) for 17 studies of PCI. From a Bayesian binomial random-effect model, the absolute risk estimate for stroke was 1.4% in patients treated with on-pu...
Source: American Heart Journal - August 19, 2013 Category: Cardiology Authors: Tullio Palmerini, Giuseppe Biondi-Zoccai, Diego Della Riva, Andrea Mariani, Gregg W. Stone Tags: Letters to the Editor Source Type: research
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions: LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 4, 2013 Category: Cardiology Authors: Steven P. Marso, Neil R. Poulter, Steven E. Nissen, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Kirstine Brown Frandsen, Alan C. Moses, John B. Bus Tags: Trial Design Source Type: research
Rationale and design of the Steroids in Cardiac Surgery trial
Conclusions: SIRS will lead to a better understanding of the safety and efficacy of prophylactic steroids for cardiac surgery requiring CBP.
Source: American Heart Journal - March 3, 2014 Category: Cardiology Authors: Richard Whitlock, Kevin Teoh, Jessica Vincent, P.J. Devereaux, Andre Lamy, Domenico Paparella, Yunxia Zuo, Daniel I. Sessler, Pallav Shah, Juan-Carlos Villar, Ganesan Karthikeyan, Gerard Urrútia, Alvaro Alvezum, Xiaohe Zhang, Seyed Hesameddin Abbasi, Hon Tags: Trial Design Source Type: research
